الهيموفيليا في الأردن: معضلة العبء الاقتصادي للأمراض النادرة
DOI:
https://doi.org/10.35516/jjps.v16i2.1462الكلمات المفتاحية:
الهيموفيليا، الأردن، العبء الأقتصادي، 2019الملخص
الأردن بلد من الشريحة العليا من البلدان متوسطة الدخل ذات الإنفاق العالي على المستحضرات الصيدلانية. واجه تطوير علاجات جديدة للأمراض النادرة (مثل الهيموفيليا) عقبات كبيرة فيما يتعلق بالتكلفة الاقتصادية للمرض والعلاج. هدفت هذه الدراسة لتقدير الإنفاق السنوي الحالي على علاج الهيموفيليا في الأردن والأثر المالي لإستخدام دواء جديد (Emicizumab) استخدم مؤخرا لعلاج مرضى الهيموفيليا في الأردن. الأساليب: بناء على مراجعة الأدبيات، تم تحديد التكاليف الطبية المباشرة، وتم استخلاص عناصر التكاليف المطلوبة من الممارسة الفعلية في الأردن من لجنة خبراء، وتم عقد اجتماع لهذه اللجنة مع مجموعة من المختصين بعد شهر واحد من أجل تقدير عدد مرضى الإيموفيليا في الأردن، والتعرف على كميات العلاج حسب الطلب وأسعارها لهؤلاء المرضى. كما تم تحديد جميع التكاليف الطبية ذات الصلة (مثل النزيف، والعدد المقدر لأيام المكوث في المستشفى و/ أو وحدة العناية المركزة لكل حالة نزيف). تم حساب تقدير الاستهلاك السنوي لكميات وتكلفة العلاج الحالي عند الطلب ومقارنته بسيناريوهات إضافة العلاج الجديد (Emicizumab). أظهرت النتائج أن الأثر المالي لاستخدام Emicizumab S.C. بدلا من VIIa IV Recombinant Factor على ميزانية الحكومة الأردنية سيكون 425,747 دينار أردني (601,338 دولار) سنويا. الإستنتاج: قد تكون المزايا الاقتصادية لعلاج الهيموفيليا الجديد كبيرة جدا للمرضى.
المراجع
(1) Alabbadi, I., Massad, E., Taani, N. et al. (2022). Exploring the Economic Aspects of β-Thalassemia in Jordan in. Jordan J. Pharm. Sci. 2019; 15(3), 390–404.
https://doi.org/10.35516/jjps.v15i3.412
(2) High Health Council-Jordan. Jordan National Health Accounts for 2016 – 2017 Fiscal Years 2019. [https://jordankmportal.com/resources/jordan-national-health-accounts]. Accessed in Oct 2020
(3) Ministry of Health-Jordan. Ministry of Health Annual Report. 2019.
[https://www.moh.gov.om/en/web/statistics/annual-reports] Accessed in Oct 2020
(4) Copley-Merriman K. Rare Diseases: Addressing the Challenges in Diagnosis, Drug Approval, and Patient Access. Value in Health. 2018; 21: 491-92.
(5) Richter T, Nestler-Parr S, Babela R. et al. Rare Disease Terminology and Definitions-A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group. Value in Health. 2015; 18: 906-14.
(6) Auvin S, Irwin J, Abi-Aad P. et al. The Problem of Rarity: Estimation of Prevalence in Rare Disease. Value Health. 2018; 21: 501-07.
(7) Berntorp E. Future of haemophilia outcome assessment: registries are key to optimized treatment. Journal of Internal Medicine. 2016; 279: 498-501.
(8) Chen CX, Baker JR, Nichol MB. Economic Burden of Illness among Persons with Hemophilia B from HUGS Vb: Examining the Association of Severity and Treatment Regimens with Costs and Annual Bleed Rates. Value in Health. 2017; 20: 1074-82.
(9) O'Hara J, Hughes D, Camp C. et al. The cost of severe haemophilia in Europe: the CHESS study. Orphanet Journal of Rare Diseases. 2017; 12: 8.
(10) Self-reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study.
(11) The Prevalence and Treatment Status of Hemophilia in India, Russia, Taiwan and Turkey: A Systematic Review and Meta-Analysis.
(12) O'Hara J, Walsh S, Camp C. et al. The relationship between target joints and direct resource use in severe haemophilia. Health Economics Review. 2018; 8.
(13) Buckley B, Dreyfus J, Prasad M. et al. Burden of illness and costs among paediatric haemophilia patients with and without central venous access devices treated in US hospitals. Haemophilia. 2018; 24: E93-E102.
(14) Institute for Clinical and economic review (ICER). Emicizumab for Hemophilia A: Effectiveness and value. 2017. [https:icer.org] on line data base accessed in Dec 2020
(15) O'Hara J, Walsh S, Camp C. et al. The impact of severe haemophilia and the presence of target joints on health-related quality-of-life. Health and Quality of Life Outcomes. 2018; 16.
(16) Prevalence and severity by age and other clinical correlates of haemophilic arthropathy of the elbow, knee and ankle among Taiwanese patients with haemophilia.
(17) The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia Results from the Saudi national hemophilia screening program.
(18) Cavazza M, Kodra Y, Armeni P. et al. Social/economic costs and quality of life in patients with haemophilia in Europe. European Journal of Health Economics. 2016; 17: 53-65.
(19) Mousavi SH, Mesbah-Namin SA, Rezaie N. et al. Prevalence of factor VIII inhibitors among Afghan patients with hemophilia A: a first report. Blood Coagul Fibrinolysis. 2018; 29: 697-700.
(20) Sánchez-Vanegas G, Linares A, Sarmiento I. et al. Cost of Patients With Hemophilia A and High-Titer Inhibitors in Colombia. Value Health Reg Issues. 2019; 20: 164-71.
(21) Jimenez-Yuste V, Auerswald G, Benson G. et al. Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future. Blood Transfusion. 2014; 12: 314-19.
(22) Castro HE, Briceno MF, Casas CP. et al. The History and Evolution of the Clinical Effectiveness of Haemophilia Type A Treatment: A Systematic Review. Indian Journal of Hematology and Blood Transfusion. 2014; 30: 1-11.
(23) Carlos-Rivera F, Gasca-Pineda R, Majluf-Cruz A. et al. Economic Impact of Hemophilia type A and B in Mexico. Gaceta Medica De Mexico. 2016; 152: 19-29.
(24) Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males A Meta-analytic Approach Using National Registries.
(25) Santos AS, Guerra-Junior AA, Noronha KVMS, et al. The Price of Substitute Technologies. Value Health Reg Issues. 2019; 20: 154-58.
(26) Zhou ZY, Koerper MA, Johnson KA. et al.Burden of illness: direct and indirect costs among persons with hemophilia A in the United States. Journal of Medical Economics. 2015; 18: 457-65.
(27) Heemstra HE, Zwaan T, Hemels M.et al. Cost of severe haemophilia in Toronto. Haemophilia. 2005; 11: 254-60.
(28) Team JH. Personal interview with each member of the Jordanian Hemophilia Team followed by a discussion forum reaching a consensus about topics of discussion. 2019.
(29) Administration JFaD. Medication prices in the private sector. 2019.
(30) Jordan. The Hashemite kingdom of Jordan - Jordan Food and Drug Administration Laws and regulations. In: Administration JFaD, ed., 2008.
(31) Ollendorf DA, Chapman RH, Pearson SD. Evaluating and Valuing Drugs for Rare Conditions: No Easy Answers. Value in Health. 2018; 21: 547-52.
(32) Detiček A, Locatelli I, Kos M. Patient Access to Medicines for Rare Diseases in European Countries. Value Health. 2018; 21: 553-60.
(33) Magalhaes M. Can Severity Outweigh Smaller Numbers? A Deliberative Perspective from Canada. Value Health. 2018; 21: 532-37.
(34) Pocoski J, Benjamin K, Michaels LA. et al. An overview of current trends and gaps in patient-reported outcome measures used in haemophilia. European Journal of Haematology. 2014; 93: 1-8.
(35) Ibrahim Alabbadi: Budget impact of adding one Dipeptidyl peptidase-4 inhibitor to Ministry of Health Jordan tender list in the treatment of Type II Diabetes Mellitus. Jordan J. Pharm. Sci. 2015; 8, 3: 173-180.
(36) Messori A. Inhibitors in Hemophilia A: A Pharmacoeconomic Perspective. Seminars in Thrombosis and Hemostasis. 2018; 44: 561-67.
(37) Hammad EA, Fardous T, Abbadi I. Costs of hospital services in Jordan. International Journal of Health Planning and Management. 2017; 32: 388-99.
